Detail akcie MiNK Therap Rg online

Business Summary: MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Mink Therapeutics Inc revenues was not reported. Net loss increased 19% to $9.9M. Higher net loss reflects Other Operating Income/Expense decrease of 100% to $1K (income), General and administrative - Balancin increase of 71% to $3.2M (expense), Change in fair value of related party no increase from $350K to $726K (expense).